Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by goldtechon Nov 04, 2024 6:15pm
118 Views
Post# 36296170

All the marbles

All the marblesThe global alzheimer's therapeutics market size was valued at USD 4.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 19.99% from 2023 to 2030. The rising prevalence of Alzheimer's Disease (AD) and approval of disease-modifying therapies are expected to fuel market growth.

So to sound like a broken record and to appeal to your sense of greed, if and I do mean if you show significant efficacy with minimal side effects, then you beat all the majors in this field and will take off on one of musks rockets. We will have an indication sometime in June, but our contracted CRO will be able to tell us after a month or so of dosing the first cohort. Gut wrenching times ahead and if this works all out other antibodies will get fast tracked.

<< Previous
Bullboard Posts
Next >>